Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2015-06-15 | PMID 25722197
Luetkemeyer Anne F, Rosenkranz Susan L, Lu Darlene and 7 more
Genes: NAT2
